Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
QLGN Qualigen Therapeutics Inc
JOFF JOFF Fintech Acquisition Corp
IR Ingersoll Rand Inc
TGT Target Corp
CCLP CSI Compressco LP
BIOT Biotech Acquisition Co
XNXNX Nuveen New York Select Tax Free Income Portfolio
DHHC DiamondHead Holdings Corp
WFC Wells Fargo & Co
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.

Postmarket

Last Trade
Delayed
$0.439
0.0022 (0.50%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$0.4368
Day's Change
-0.0092 (-2.06%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
0.45
Day's Low
0.41
Volume
(Light)
Volume:
1,064,372

10-day average volume:
3,350,512
1,064,372
Latest Earnings Beat Consensus (Q3 ending 09/2022)Next Earnings Announcement
Q3
Announced November 3, 2022
-$0.19Q3 Consensus
of 5 analysts
-$0.23Difference from
consensus
18.10%
Q4 Earnings
will announce
(Unconfirmed) March 6, 2023

Quarterly Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

AGLE's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.